Inactive/Delisted stock
Elevation Oncology Stock (NASDAQ:ELEV)
Previous Close
$0.51
52W Range
$0.41 - $5.83
50D Avg
$0.63
200D Avg
$1.27
Market Cap
$30.25M
Avg Vol (3M)
$2.28M
Beta
1.38
Div Yield
-
ELEV Company Profile
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.